CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
1.010
-0.050 (-4.72%)
At close: Jun 5, 2025, 4:00 PM
1.020
+0.010 (0.99%)
After-hours: Jun 5, 2025, 4:19 PM EDT

Company Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.

The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies.

It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals logo
Country United States
Founded 2017
IPO Date Nov 8, 2019
Industry Biotechnology
Sector Healthcare
Employees 5
CEO John Climaco

Contact Details

Address:
2100 West Loop South, Suite 900
Houston, Texas 77027
United States
Phone 800-946-9185
Website cnspharma.com

Stock Details

Ticker Symbol CNSP
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001729427
CUSIP Number 18978H409
ISIN Number US18978H4092
Employer ID 82-2318545
SIC Code 2834

Key Executives

Name Position
John Michael Climaco Esq., J.D. Chief Executive Officer, President and Director
Christopher S. Downs CPA, CTP, FP&A Chief Financial Officer
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer
Dr. Waldemar Priebe Ph.D. Founder
Dr. Donald H. Picker Ph.D. Chief Science Officer

Latest SEC Filings

Date Type Title
May 15, 2025 10-Q Quarterly Report
May 15, 2025 8-K Current Report
May 14, 2025 424B4 Prospectus
May 13, 2025 EFFECT Notice of Effectiveness
May 12, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 30, 2025 10-K/A [Amend] Annual report
Apr 14, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Apr 9, 2025 8-K Current Report
Apr 7, 2025 DRS [Cover] Draft Registration Statement
Mar 31, 2025 8-K Current Report